In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Share the Wealth? No Thanks

Executive Summary

Biopharmaceutical companies are doing the math and increasingly coming to one conclusion: it's in their economic interests to buy out a biotech partner. Genentech Inc.'s $919 million all-cash acquisition of its omalizumab (Xolair) partner Tanox Inc. in November is one of the most recent examples.

Related Content

Reviewing Five Years of Big Pharma's Biotech Acquisitions
Co-Promotes: A Marketplace Reality, But Do They Make Sense?
Baked-In Goodness: Shire Buys New River for $2.6 Billion
A Look Back at 2006: The Pipeline Challenge
Novartis' M&A Machine
European Consolidation: Serious Competition for Big Pharma?
Amgen/Abgenix: All About a Drug
Amgen/Abgenix: All About a Drug
Tanox: Once Is Not Enough
Tanox: Once Is Not Enough


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts